|[January 28, 2013]
Nordion Appoints Mr. Grant Gardiner as SVP and General Counsel
OTTAWA, Ontario --(Business Wire)--
Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and
services to the global health science market, today announced it is
appointing Grant Gardiner as Senior Vice President, General Counsel &
Corporate Secretary. Mr. Gardiner will serve as the Corporation's legal
officer responsible for all global legal matters, effective March 18,
"We are very pleased to welcome Grant to the Nordion management team.
With more than 19 years of experience, Grant is a seasoned lawyer with a
strong understanding of business and global market dynamics. His proven
expertise in leading cross-listed, publicly traded companies through
complex legal, governance and compliance landscapes with a business
focus will be a significant asset to Nordion," said Mr. Steve West,
Chief Executive Officer, Nordion Inc. "Grant is expected to play an
instrumental role in the execution of our business strategy globally."
Mr. Gardiner joins Nordion from Research in Motion (News - Alert) Limited (RIM) where
he currently serves as Vice-President, Associate General Counsel and
acted as Corporate Secretary to RIM's Board of Directors for
approximately four years. During his tenure at RIM, which began in 2008,
Grant has advised on securities matters, mergers & acquisitions, ethics
and compliance programs as well as Board and Corporate Governance
Withleadership roles at other leading global, publicly-traded companies
such as Cognos Inc. (now IBM (News - Alert)) and JDS Uniphase, Mr. Gardiner's
experience includes mergers and acquisitions, corporate governance,
commercial transactions, as well as securities and anti-corruption law.
He holds a Bachelor of Business Administration from the University of
Prince Edward Island (1988), an L.L.B. from Osgoode Hall Law School
(1991) and was admitted to the Ontario Bar in 1993.
About Nordion Inc.
Nordion Inc. (TSX: NDN) (NYSE: NDZ) is a global health science company
that provides market-leading products used for the prevention, diagnosis
and treatment of disease. We are a leading provider of targeted
therapies, sterilization technologies, and medical isotopes that benefit
the lives of millions of people in more than 60 countries around the
world. Our products are used daily by pharmaceutical and biotechnology
companies, medical-device manufacturers, hospitals, clinics and research
laboratories. Nordion has approximately 500 highly skilled employees
worldwide. Find out more at www.nordion.com
and follow us at http://twitter.com/NordionInc.
Certain statements contained in this news release constitute
"forward-looking statements". These statements are based on current
beliefs and assumptions of management, however are subject to known and
unknown risks, uncertainties and other factors that may cause actual
results to differ materially from the forward-looking statements in this
news release. For additional information with respect to certain of
these beliefs, assumptions, risks and uncertainties, please refer to
Nordion's Annual Information Form for fiscal 2012 available on SEDAR at www.sedar.com
and on EDGAR on www.sec.gov.
[ Back To IBM News 's Homepage ]